不同肾功能人群中西泊酚及其代谢物M4的总浓度与游离浓度群体药代动力学和药效学研究
本研究在24名不同肾功能中国受试者中,基于401对西泊酚和459对M4的总浓度与游离浓度数据及2190个BIS数据,建立群体PK/PD模型。结果显示血红蛋白影响西泊酚中央室清除率,尿酸影响M4中央室清除率及蛋白结合率,但协变量不影响药效学。模拟表明标签推荐剂量适用于麻醉诱导,轻中度肾功能不全无需调整剂量。
要点
- 轻中度肾功能不全患者使用西泊酚麻醉诱导无需调整剂量。
- 血红蛋白是西泊酚中央室清除率的协变量。
- 尿酸影响M4中央室清除率及蛋白结合率,但不影响药效学。
核心结论
- 所建模型完整描述了西泊酚的群体PK和PD特征。
- 轻中度肾功能不全患者无需调整西泊酚剂量。
研究设计与样本
- 基于24名不同肾功能中国受试者,共401对西泊酚和459对M4的总浓度与游离浓度数据及2190个BIS数据建立群体PK/PD模型。
- 采用逐步法筛选影响西泊酚PK和PD变异的协变量,并通过基于模型的模拟确定最佳诱导剂量方案。
主要发现
- 游离西泊酚PK最佳描述为三室模型,游离M4 PK为二室模型。
- 西泊酚和M4的总浓度与游离浓度通过线性蛋白结合模型连接。
- 西泊酚血药浓度与BIS关系最佳描述为带有二室生物相分布室的抑制性Sigmoidal Emax模型。
- 血红蛋白是西泊酚中央室清除率的协变量,尿酸是M4中央室清除率及蛋白结合率kB的协变量。
- 纳入的协变量对西泊酚PD无影响。
关键数值与推荐
- 模拟结果显示标签推荐剂量方案足以用于麻醉诱导。
临床怎么用
- 轻中度肾功能不全患者使用西泊酚麻醉诱导时可按标签推荐剂量给药,无需调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to develop a population pharmacokinetic (PK) model to simultaneously describe both total and unbound concentrations of ciprofol and its major glucuronide metabolite, M4, and to link it to the population pharmacodynamics (PD) model in subjects with various renal functions. METHODS: A total of 401 and 459 pairs of total and unbound plasma concentrations of ciprofol and M4, respectively, as well as 2190 bispectral index (BIS) data from 24 Chinese subjects with various renal functions were available. Covariates that may potentially contribute to the PK and PD variability of ciprofol were screened using a stepwise procedure. The optimal ciprofol induction dosing regimen was determined by model-based simulations. RESULTS: The PK of unbound ciprofol could best be described by a three-compartment model, while a two-compartment model could adequately describe unbound M4 PK. The concentrations of total and unbound ciprofol and M4 were linked using a linear protein binding model. The relationship between plasma concentrations of ciprofol and BIS data was best described by an inhibitory sigmoidal Emax model with a two-compartment biophase distribution compartment. Hemoglobin was the identified covariate determining the central compartment clearance of ciprofol; uric acid was a covariate affecting the central compartment clearance of M4 and protein binding rate, kB . The included covariates had no effect on the PD of ciprofol. Simulation results indicated that the label-recommended dose regimen was adequate for anaesthesia induction. CONCLUSIONS: The developed model fully characterized the population PK and PD profiles of ciprofol. No dose adjustment is required in patients with mild and moderate renal impairment.
引用
- Liu SB, Yao X, Tao J, et al. Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions. Br J Clin Pharmacol. 2022. PMID: 36217805. doi:10.1111/bcp.15561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。